Who is sponsoring NCT05102058?

NCT05102058 is sponsored by Istanbul University.

What drugs are being tested in NCT05102058?

Interventions in NCT05102058: Magnesium-Dexmedetomidine.

What condition does NCT05102058 study?

NCT05102058 studies Phaeochromocytoma Crisis, Hemodynamic Instability.

Is NCT05102058 still recruiting?

NCT05102058 is currently completed. Last updated 1 November 2021.

Last reviewed 2021-11-01 · How we verify

NCT05102058

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magnesium and Dexmedetomidine in Pheochromocytoma

Completed Last updated 1 November 2021

What this trial tests

trial testing Magnesium-Dexmedetomidine in Phaeochromocytoma Crisis in 108 participants. Completed in 1 March 2020.

Timeline

1 January 2011

Primary endpoint
1 March 2020

1 March 2020

Quick facts

Lead sponsor	Istanbul University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	108
Start date	1 January 2011
Primary completion	1 March 2020
Estimated completion	1 March 2020

Drugs / interventions tested

Magnesium-Dexmedetomidine — full drug profile →

Conditions studied

Phaeochromocytoma Crisis — all drugs for Phaeochromocytoma Crisis →
Hemodynamic Instability — all drugs for Hemodynamic Instability →

Sponsor

Istanbul University

Who can join

Adults 18 to 75, any sex, with Phaeochromocytoma Crisis or Hemodynamic Instability. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anesthesia management of pheochromocytoma excision surgery is associated with severe hemodynamic fluctuations.The objective of this study was to compare the hypertensive episodes requiring sodium nitroprusside administration between the group treated with magnesium-dexmedetomidine and conventional group in pheochromocytoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Magnesium and dexmedetomidine combination reduces sodium nitroprusside requirement in laparoscopic pheochromocytoma.
Sivrikoz N, Turhan Ö, Yavru HA, Altun D, et al · · 2022 · cited 1× · PMID 36282168 · DOI 10.14744/tjtes.2022.92672

Verify or expand the search:

Other Istanbul University trials

Trials by the same sponsor.

NCT07472946 — Whole-Body Vibration Exercise in Patients With Parkinson's Disease · NA · not yet recruiting
NCT07433894 — Scoliosis and Functional Outcomes in Children With Juvenile Idiopathic Arthritis · not yet recruiting
NCT07420049 — Turkish Adaptation of the CTS-6 Evaluation Tool: A Validation and Reliability Study · not yet recruiting
NCT07415967 — The Effect of a Dual-Task Technique-Based Exercise Program on Clinical Outcomes in Rotator Cuff Related Shoulder Pain · NA · recruiting
NCT07473024 — pEEG-Guided Anesthesia and Behavioral Outcomes in Children · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05102058 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Istanbul University
Last refreshed: 1 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05102058.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing